Dimensional Fund Advisors LP Has $355,000 Stock Holdings in AC Immune SA (NASDAQ:ACIU)

Dimensional Fund Advisors LP boosted its position in AC Immune SA (NASDAQ:ACIU) by 130.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,410 shares of the company’s stock after buying an additional 74,358 shares during the period. Dimensional Fund Advisors LP owned approximately 0.13% of AC Immune worth $355,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ACIU. Renaissance Technologies LLC raised its stake in shares of AC Immune by 14.6% in the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after purchasing an additional 94,191 shares during the last quarter. RPO LLC purchased a new position in shares of AC Immune during the 4th quarter valued at $51,000. Quinn Opportunity Partners LLC purchased a new position in shares of AC Immune during the 4th quarter valued at $27,000. Finally, Geode Capital Management LLC lifted its position in shares of AC Immune by 9.9% during the 4th quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock valued at $173,000 after buying an additional 5,794 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ACIU. StockNews.com raised AC Immune from a “hold” rating to a “buy” rating in a report on Tuesday. HC Wainwright dropped their price objective on AC Immune from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 1st.

AC Immune Stock Performance

Shares of ACIU opened at $1.71 on Friday. The stock’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $2.47. The stock has a market capitalization of $171.70 million, a price-to-earnings ratio of -3.72 and a beta of 1.62. AC Immune SA has a 52-week low of $1.43 and a 52-week high of $4.98.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $1.12 million during the quarter, compared to analysts’ expectations of $1.99 million. On average, research analysts forecast that AC Immune SA will post -0.62 earnings per share for the current fiscal year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.